The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).
 
Wei Li
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
HuiWen Ma
No Relationships to Disclose
 
Huijie Fan
No Relationships to Disclose
 
Kunyan Li
No Relationships to Disclose
 
Huijuan Wu
No Relationships to Disclose
 
Qitao Yu
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Xue Meng
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Xintian Qin
No Relationships to Disclose
 
Ziping Wang
No Relationships to Disclose
 
Yunpeng Liu
No Relationships to Disclose
 
Min Tao
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Yong Fang
No Relationships to Disclose
 
Ping Sun
No Relationships to Disclose
 
Kaihua Lu
No Relationships to Disclose
 
Jingxun Wu
No Relationships to Disclose
 
Caicun Zhou
Honoraria - Boehringer Ingelheim; Hengrui Therapeutics; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical